Sealed Air Corp Essay

canines by waiting for Hemopure market releaseHemopure's Competitors and Market Potentials

Regardless of what direct competitors Baxter and Northfield are pricing their human RBC substitutes, there has been no research that shows hospitals are willing to pay $800 per unit for the faux blood. According to data for current blood transfusions, patients are paying, at the highest estimates, $225 and $425/unit for anonymous and autologous donations, respectively (Case Exhibit 6). If Hemopure is priced at $800/unit to hospitals, patients and/or their insurance provider could be forced to pay upwards of $1,000/unit after additional charges for handling and administration, which is 2 to 5 times more than the highest estimates for current methods. With the current standard of care of donated human blood being, "for the most part, safe and effective," most patients receiving transfusions will only benefit little from Hemopure. The minimal benefit derived from Hemopure cannot justify its high price tag.Hemopure's Competitors and Market Potentials

Regardless of what direct competitors Baxter and Northfield are pricing their human RBC substitutes, there has been no research that shows hospitals are willing to pay $800 per unit for the faux blood. According to data for current blood transfusions, patients are paying, at the highest estimates, $225 and $425/unit for anonymous and autologous donations, respectively (Case Exhibit 6). If Hemopure is priced at $800/unit to hospitals, patients and/or their insurance provider could be forced to pay upwards of $1,000/unit after additional charges for handling and administration, which is 2 to 5 times more than the highest estimates for current methods. With the current standard of care of donated human blood being, "for the most part, safe and effective," most patients receiving transfusions will only benefit little from Hemopure. The minimal benefit derived from Hemopure cannot justify its high price tag.Hemopure's Competitors and Market Potentials

Regardless of what direct competitors Baxter and Northfield are pricing their human RBC substitutes, there has been no research that shows hospitals are willing to pay $800 per unit for the faux blood. According to data for current blood transfusions, patients are paying, at the highest estimates, $225 and $425/unit for anonymous and autologous donations, respectively (Case Exhibit 6). If Hemopure is priced at $800/unit to hospitals, patients and/or their insurance provider could be forced to pay upwards of $1,000/unit after additional charges for handling and administration, which is 2 to 5 times more than the highest estimates for current methods. With the current standard of care of donated human blood being, "for the most part, safe and effective," most patients receiving transfusions will only benefit little from Hemopure. The minimal benefit derived from Hemopure cannot